Mecamylamine Hydrochloride

CHEMBL1237082 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
203.8 g/mol
LogP
Phase
4

A hydrochloride salt form of mecamylamine, a ganglionic blocking agent used to manage severe, treatment-resistant high blood pressure and studied for nicotine dependence treatment.

Peso Molecular

203,7500 g/mol

TPSA

12,00 Ų

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNC1(C)C2CCC(C2)C1(C)C.Cl

InChI

InChI=1S/C11H21N.ClH/c1-10(2)8-5-6-9(7-8)11(10,3)12-4;/h8-9,12H,5-7H2,1-4H3;1H

Molecular Formula

C11H22ClN

HBD / HBA

2 / 1

Ligações Rotacionáveis

1

Átomos Pesados

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A hydrochloride salt form of mecamylamine, a ganglionic blocking agent used to manage severe, treatment-resistant high blood pressure and studied for nicotine dependence treatment.

Yes, Mecamylamine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237082. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 13221. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.